Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Synlogic Inc (SYBX) USD0.001

Sell:$3.00 Buy:$3.33 Change: $0.1 (3.13%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$3.00
Buy:$3.33
Change: $0.1 (3.13%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$3.00
Buy:$3.33
Change: $0.1 (3.13%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.

Contact details

Address:
301 Binney St Ste 402
CAMBRIDGE
02142-1030
United States
Telephone:
+1 (617) 4019975
Website:
https://www.synlogictx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SYBX
ISIN:
US87166L1008
Market cap:
$166.02 million
Shares in issue:
52.37 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Aoife Brennan
    President, Chief Executive Officer, Director
  • Gregg Beloff
    Interim Chief Financial Officer
  • Daniel Rosan
    Senior Vice President, Head of Finance
  • Antoine Awad
    Chief Operating Officer, Head of Technical Operation
  • Jamie Austin
    Vice President, Head of Incoming and Regulatory Affairs
  • Caroline Kurtz
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.